Feature | May 16, 2013

Leviticus Cardio Completes Successful Wireless Energy System for VADs Animal Trial

The animal trials were done using the Leviticus CET system and Jarvik Heart VAD

VAD wireless power transfer system

May 16, 2013 — Leviticus Cardio performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The surgery was performed at Assaf Harofeh Hospital and produced a 75 percent full system efficiency rate as compared with 78 percent efficiency in vitro.


The animal trials were done using the Leviticus CET system and Jarvik Heart VAD. The CET system performed the energy transfer to the animal body and controlled the VAD pump operation.


In vitro lab tests were conducted using several commercial VAD systems of Thoratec, Heartware, Jarvik Heart and Cleveland Heart. In all these tests, the Leviticus CET system was used to transfer the energy and to control the VAD pumping operation using the Leviticus advanced controller.


VADs are used to extend the lives of thousands of patients suffering from chronic heart failure or waiting for a heart transplant. Leviticus Cardio's wireless CET system powers the VAD without wires, thereby avoiding possible complications like dangerous infections, repeated hospitalizations and severely limiting mobility. In addition, the Leviticus Cardio's system can easily be removed for limited periods of time to give patients complete freedom of movement without any external device attached.


For more information: www.leviticus-cardio.com


Related Content

MRI, cardiovascular risk factors, Alzheimer's disease, early predictors
News | Cardiac Imaging| August 04, 2015
Specific cardiovascular risk factors are associated with smaller regional brain volumes that may be early indicators of...
Sunshine Heart, C-Pulse, circulatory support system, update
News | Heart Failure| August 03, 2015
Sunshine Heart announced plans to commence a first-in-human study using its novel C-Pulse transcutaneous energy...
Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
MSCs, stem cells, end-stageheart failure, retrograde, coronary sinus,
News | Stem Cell Therapies| July 29, 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus...
heart failure, Adaptive CRT trial, AdaptivCRT algorithm, readmissions
News | Heart Failure| July 22, 2015
Heart failure patients had a significantly lower chance of being readmitted within 30 days of discharge when treated...
Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA
News | Heart Valve Repair| July 22, 2015
Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
HeartMate PHP, Thoratec, St. Jude medical

The HeartMate PHP (percutaneous heart pump) is the latest acute hemodynamic support technology released by Thoratec, which recently received CE mark in Europe. The PHP is currently in U.S.clinical trials.

Feature | Ventricular Assist Devices (VAD)| July 22, 2015
St. Jude Medical and Thoratec announced that the boards of directors of both companies have unanimously approved a...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies| July 21, 2015
Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to...
UNC, biomarkers, severe heart disease, fructosamine, LDL cholesterol, Nichols
News | Cardiac Diagnostics| July 21, 2015
Insulin resistance affects tens of millions of Americans and is a big risk factor for heart disease. Yet, some people...
Feature | Atrial Fibrillation| July 20, 2015
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with...
Overlay Init